It's looking good !
Excerpt----
Patrys’ Chief Executive Officer and Managing Director, Dr James Campbell commented: “We are excited about progress made with PAT‐DX1, particularly the pre‐clinical data that has been reported since September 2017 and the new discoveries around localization of tumor metastases.
Along with our co‐applicant, Yale University, we have filed a provisional patent application to protect the panel of 3E10 variants generated as part of the in silico design work.
This provides an additional layer of protection to the Deoxymab intellectual property portfolio, and strengthens Patrys’ leading position in DNA damage repair therapeutics.”
Ann: Publication and Patent Filing for Humanized Version of 3E10, page-2
-
- There are more pages in this discussion • 19 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $6.172M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.3¢ | $10.97K | 3.626M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 41 | 31554019 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 27089307 | 15 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| PAB (ASX) Chart |